Tissue factor-dependent coagulation activation in intracranial neoplasms: a comparative study.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
pubmed:
28
9
2022
medline:
24
11
2022
entrez:
27
9
2022
Statut:
ppublish
Résumé
The aim of the study was to investigate the concentration and activity of tissue factor (TF) and Tissue factor pathway inhibitor (TFPI) as well as the concentration of thrombin-antithrombin (TAT) complexes in patients with primary and metastatic intracranial neoplasms. The study included 69 patients with an average age of 62 years. Twenty-one patients were diagnosed with gliomas, 18 meningioma stage II (M) patients, and 30 metastatic brain tumour cases (Meta). The control group consisted of 30 individuals with a mean age of 57 years. In the plasma of all the participants and in tumour tissue-derived homogenate, the concentrations and activities of TF, TFPI, the concentration of TAT complexes and the concentration of total protein were measured. The results were converted per 1 mg of protein. The concentration of TF was over 80 times higher in the tumour tissue-derived homogenate in respect to patients' plasma levels. Plasma TF activity in intracranial cancer patients was almost six times higher compared with noncancer counterparts, while in the tumour tissue-derived homogenate it was more than 14 times higher than in the intracranial cancer patients' plasma, whereas the concentration of TFPI in the tumour tissue-derived homogenate was significantly lower than in the patients' plasma. However, a significantly higher TFPI activity in the tumour tissue derived than in the patients' plasma was reported. The high concentration and activity of TF, along with the coexisting low concentration and activity of TFPI in the plasma of intracranial tumour patients, is associated with a higher prothrombotic risk in these patients.
Identifiants
pubmed: 36165076
doi: 10.1097/MBC.0000000000001164
pii: 00001721-202212000-00002
doi:
Substances chimiques
Thromboplastin
9035-58-9
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
438-448Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Trousseau A. Cormack JR. Phlegmasia alba dolens. Clinique Medicale de l’Hotel-Dieu de Paris (Lectures on ClinicalMedicine at the Hotel-Dieu, Paris), vol. 5 . London, UK: New Sydenham Society; 1872. 281–332.
Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017; 130:1499–1506.
Cimmino G, Cirillo P. Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis. Cardiovasc Diagn Ther 2018; 8:581–593.
Owens A, Mackmann N. Tissue factor and thrombosis. Thromb Haemost 2010; 104:432–439.
Zwicker JI, Trenor CC 3rd, Furie BC, Furie B. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011; 31:728–733.
Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834–4838.
Mitrugno A, Tormoen GW, Kuhn P, McCarty OJ. The prothrombotic activity of cancer cells in the circulation. Blood Rev 2016; 30:11–19.
Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost 2014; 40:325–331.
Cote DJ, Smith TR. Venous thromboembolism in brain patients. J Clin Neurosci 2016; 25:13–18.
Peeters MCM, Zwinkels H, Koekkoek JAF, Vos MJ, Dirven L, Taphoorn MJB. The impact of the timing of health-related quality of life assessments on the actual results in glioma patients: a randomized prospective study. Cancers (Basel) 2020; 12:2172.
Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol 2012; 14 Suppl 4: (Suppl 4): iv73–iv80.
Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83:164–170.
Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, Imamura M. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000; 88:295–301.
Chen L, Luo G, Tan Y, Wei J, Wu C, Zheng L, et al. Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochem 2010; 112:233–239.
Yamashita H, Kitayama J, Ishikawa M, Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 2007; 95:324–331.
Maciel EO, Carvalhal GF, da Silva VD, Batista EL Jr, Garicochea B. Increased tissue factor expression and poor nephroblastoma prognosis. J Urol 2009; 182:1594–1599.
Guan M, Jin J, Su B, Liu WW, Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002; 35:321–325.
Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor in glioma. Noshuyo Byori 1996; 13:115–118.
Ishimaru K, Hirano H, Yamahata H, Takeshima H, Niiro M, Kuratsu J. The expression of tissue factor correlates with proliferative ability in meningioma. Oncol Rep 2003; 10:1133–1137.
Gay LJ, Day J, LeBoeuf S, Ritland M, Ruggeri ZM, Ruf W, Felding BH. Brain metastasis depends on tumor cell initiated coagulation. Abstract B199, AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment, San Diego, CA, 2014.
Ruf W. Tissue factor and cancer. Thromb Res 2012; 130 Suppl 1:S84–S87.
Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992; 52:3267–3272.
Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991; 87:229–236.
Booden MA, Eckert LB, Der CJ, Trejo J. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol 2004; 24:1990–1999.
Han X, Guo B, Li Y, Zhu B. Tissue factor in tumor microenvironment: a systematic review. J Hematol Oncol 2014; 7:54.
Monteiro RQ, Lima LG, Gonçalves NP, DE Souza MR, Leal AC, Demasi MA, et al. Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model. Oncol Lett 2016; 12:315–322.
Sarder A, Ali K, Pokharel YR. Tissue factor and breast cancer. Biosci Bioeng Commun 2015; 1:20–28.
Gader AGMA. Tissue factor pathway inhibitor [TFPi]: a natural coagulation inhibitor and potential therapeutic agent - a review. J Taibah Univ Med Sci 2009; 4:15.
Che SP, DeLeonardis C, Shuler ML, Stokol T. Tissue factor-expressing tumor cells can bind to immobilized recombinant tissue factor pathway inhibitor under static and shear conditions in vitro. PLoS One 2015; 10:e0123717.
Gerlach R, Scheuer T, Böhm M, Beck J, Woszczyk A, Raabe A, et al. Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases. Neurol Res 2003; 25:335–338.